Korea¹s Medison is introducing two new Windows NT 2000-based ultrasound systems at the RSNA meeting. The SonoAce 9900 is a new fully digital system for multispecialty applica-tions. The Voluson 730 is a premium high-end fully digital sys-tem that
Korea¹s Medison is introducing two new Windows NT 2000-based ultrasound systems at the RSNA meeting. The SonoAce 9900 is a new fully digital system for multispecialty applica-tions. The Voluson 730 is a premium high-end fully digital sys-tem that replaces the Voluson 530D.
The SonoAce 9900 incorporates digital multibeam signal processing that supports phased-sector, curved, and linear array transducers. Its transducer frequency range is from 1 to 12 MHz. The system includes m-mode and color, power, and pulsed and continuous-wave Doppler. It also includes a 3-D volume quantification method, Virtual Organ Computer Aided Analysis (VOCAL), to assess volume of anatomical structures and masses.
Voluson 730¹s digital platform offers the capability to enhance the tissue information display, an increased frame rate to define fast-moving structures, and the first real-time 4-D volume imaging for a significant increase in diagnostic information.
The Voluson 730 also offers 3-D volume quantification, advanced harmonic imaging, a quad digital beamformer, and online remote diagnostics. FDA clearance is pending.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.